CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps8586
Abstract: TPS8586Background: Mesothelioma, an incurable, apoptosis-resistant cancer, represents a growing health burden but remains under-researched, with limited treatment options. Despite a significant num... read more here.
Keywords: mesothelioma; trial evaluate; iii randomized; phase iii ... See more keywords